Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Invest 1998 Mar 01;101(5):935-9
Date
04/16/1998Pubmed ID
9486961Pubmed Central ID
PMC508642DOI
10.1172/JCI2071Scopus ID
2-s2.0-0032030918 (requires institutional sign-in at Scopus site) 176 CitationsAbstract
A consistent phenotype observed in both human patients and several different mouse models of autosomal recessive polycystic kidney disease (ARPKD) is an increased activity of the epidermal growth factor receptor (EGFR) in the affected kidneys. To determine whether this increased activity of the EGFR is a functional event that is directly part of the disease pathway of renal cyst formation, we used a genetic approach to introduce a mutant EGFR with decreased tyrosine kinase activity into a murine model of ARPKD. We found that the modified form of the EGFR could block the increase in EGFR-specific tyrosine kinase activity that normally accompanies the development of renal cysts, and this correlated with an improvement in kidney function and a substantial decrease in cyst formation in the collecting ducts. These results suggest that changes in the expression of the EGFR contribute to the formation of cysts in the collecting ducts, and that drugs that target the tyrosine kinase activity of the EGFR may potentially be therapeutic in ARPKD.
Author List
Richards WG, Sweeney WE, Yoder BK, Wilkinson JE, Woychik RP, Avner EDAuthor
Ellis D. Avner MD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsBlotting, Western
ErbB Receptors
Gene Expression
Kidney
Mice
Mice, Mutant Strains
Polycystic Kidney Diseases
Protein-Tyrosine Kinases
